SCHEMBL3672666

SCHEMBL3672666

CCCOC(C)(OCCC)OCCC

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5705926 0.91
SCHEMBL15256843 0.86 KIF11 (0.37)
SCHEMBL15256816 0.86
SCHEMBL10762136 0.80 TSHR (0.44) TSHRLMNA
SCHEMBL28926933 0.80
SCHEMBL191241 0.79
SCHEMBL3022307 0.79 CA1 (0.35) TSHR
SCHEMBL28926934 0.76
SCHEMBL11374678 0.76 THRB (0.44) TSHRLMNA
SCHEMBL20145107 0.76 THRB (0.44) TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613414-A Non-azolanet Process for the preparation of tam 上海皓元医药股份有限公司 2025-03-14 CN claimed
EP-4452838-A1 PROCESS FOR REMOVING WATER FROM BIS(FLUOROSULFONYL)IMIDE SOLUTIONS SPECIALTY OPERATIONS FRANCE (FR) 2024-10-30 EP claimed
US-12059467-B2 Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same ANHUI UNIVERSITY (CN) 2024-08-13 US claimed
CN-118434672-A Method for removing water from bis (fluorosulfonyl) imide solution 法国特种经营公司 2024-08-02 CN claimed
CN-117819494-A Purification method of lithium bis (fluorosulfonyl) imide 宜都兴发化工有限公司 2024-04-05 CN claimed
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME ANHUI UNIVERSITY (CN) 2024-04-04 US claimed
CN-112110862-B Preparation method and application of 1,4,5, 6-tetrahydro-5-hydroxypyrimidine compound and hydrochloride thereof 重庆华邦制药有限公司 2023-10-17 CN claimed
EP-4242173-A1 PURIFICATION OF HYDROGEN BIS(FLUOROSULFONYL)IMIDE SPECIALTY OPERATIONS FRANCE (FR) 2023-09-13 EP claimed
WO-2023118115-A1 PROCESS FOR REMOVING WATER FROM BIS(FLUOROSULFONYL)IMIDE SOLUTIONS RHODIA OPERATIONS (FR) 2023-06-29 WO claimed
US-7750095-B2 System and method for reducing fouling in a reactor CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2010-07-06 US claimed
US-20100048837-A1 System and method for reducing fouling in a reactor CHEVRON PHILLIPS CHEMICAL COMPANY LP 2010-02-25 US claimed
US-4025539-A Process for preparing 2-substituted or unsubstituted geranyl acetic acids and esters thereof KURARAY CO., LTD. (JA) 1977-05-24 US claimed
CN-121154837-B Crosslinked nano prodrug, nano self-assembled hydrogel precursor tablet prepared from crosslinked nano prodrug and application of nano self-assembled hydrogel precursor tablet ANHUI UNIVERSITY (CN) 2026-05-26 CN disclosed
CN-119613414-A Non-azolanet Process for the preparation of tam 上海皓元医药股份有限公司 2025-03-14 CN disclosed
CN-119462662-A Midazole Synthesis method of radix Armillaricis 成都倍特药业股份有限公司 2025-02-18 CN disclosed
EP-4488317-A1 METHOD FOR PRODUCING CURABLE RESIN COMPOSITION Kaneka Corporation (JP) 2025-01-08 EP disclosed
US-7750095-B2 System and method for reducing fouling in a reactor CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2010-07-06 US disclosed
US-20100048837-A1 System and method for reducing fouling in a reactor CHEVRON PHILLIPS CHEMICAL COMPANY LP 2010-02-25 US disclosed
US-4025539-A Process for preparing 2-substituted or unsubstituted geranyl acetic acids and esters thereof KURARAY CO., LTD. (JA) 1977-05-24 US disclosed
US-3975381-A Process for preparing γ-lactone derivatives SAGAMI CHEMICAL RESEARCH CENTER (JA) 1976-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108728-A1 IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME TLR7, PON1, MYD88 TSHR 3221/4885LMNA 4613/4885
US-12059467-B2 Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same TLR7, PON1, MYD88 TSHR 3173/4885LMNA 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.